Last updated on July 2020

BEAT-meso: Bevacizumab and Atezolizumab in Malignant Pleural Mesothelioma

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions: Pleural Mesothelioma Malignant Advanced
  • Age: Between 18 - 100 Years
  • Gender: Male or Female

Inclusion Criteria:

  • Histologically confirmed advanced malignant pleural mesothelioma (all histological subtypes are eligible)
  • Not amenable for radical surgery based on local standards
  • Evaluable disease or measurable disease as assessed according to the modified response evaluation criteria for solid tumours for mesothelioma (mRECIST) v1.1
  • Availability of tumour tissue for translational research
  • Age >18 years
  • Performance Status 0-1
  • Life expectancy >3 months
  • Adequate haematological, renal and liver function
  • Completed baseline quality of life (QoL) questionnaire
  • Women of childbearing potential and sexually active men must agree to use highly effective contraception
  • Able to understand and give written informed consent and comply with trial procedures

Exclusion Criteria:

  • Prior treatment for malignant pleural mesothelioma
  • Treatment with systemic immune-stimulatory agents within 4 weeks or five half-lives of the drug prior to randomisation and during protocol treatment.
  • Treatment with systemic immunosuppressive medications within 2 weeks prior to randomisation and during protocol treatment.
  • Previous allogeneic tissue/solid organ transplant
  • Live vaccines within 4 weeks prior to first dose of protocol treatment
  • Inadequately controlled hypertension
  • Prior history of hypertensive crisis or hypertensive encephalopathy
  • Significant vascular disease within 6 months prior to randomisation
  • History of haemoptysis

Recruitment Status: Open

Brief Description Eligibility Contact Research Team

Volunteer Sign-up

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.